Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
The Canadian firm’s bispecific antibody asset improved response rates in advanced biliary tract cancer patients, potentially setting it up to become the first HER2-targeted drug approved for the disease.
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.